{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-22-012521","form_type":"8-K","ticker":"PBSV","cik":"0001304161","company_name":"Pharma-Bio Serv, Inc.","filed_at":"2022-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.320883+00:00","generated_at":"2026-06-23T09:38:56.882998+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pharma-Bio Serv Q3 revenue $4.8M, net income $0.3M down $2M YoY on SBA loan forgiveness","bullets":["Revenue for Q3 ended July 31, 2022: $4.8M, down $0.2M YoY; 9-month revenue $14.8M, up $0.2M.","Net income Q3: $0.3M vs. $2.3M prior year; prior year included $2.0M SBA loan forgiveness gain.","Repurchased 10,400 shares in Q3 and 81,303 in first nine months; 1,551,943 shares remain authorized.","CEO notes revenue growth in U.S. and European consulting markets, citing expansion opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-22-012521","json":"https://secwatch.observer/filing/0001654954-22-012521.json","markdown":"https://secwatch.observer/filing/0001654954-22-012521.md","text":"https://secwatch.observer/filing/0001654954-22-012521.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1304161/000165495422012521/0001654954-22-012521-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1304161/000165495422012521/pbsv_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:38:56.882998+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}